万邦德(002082.SZ)：石杉碱甲控释片II/III期临床试验完成100例受试者入组

Core Viewpoint - Wanbangde (002082.SZ) announced that its wholly-owned subsidiary, Wanbangde Pharmaceutical Group Co., Ltd., has completed the enrollment of 100 subjects for the Phase II/III pivotal registration clinical trial of its Class 2 new drug, Huperzine A controlled-release tablets, aimed at treating mild to moderate Alzheimer's disease dementia [1] Group 1 - Huperzine A is a cholinesterase inhibitor used to improve cognitive function, showing potential in preclinical studies to delay the progression of Alzheimer's disease and offering broad benefits, including the reduction of beta-amyloid protein, anti-inflammatory, antioxidant stress, and neuroprotective effects [1] - The company is actively advancing subject enrollment and will continue to collaborate closely with over 50 research institutions nationwide, including Xuanwu Hospital of Capital Medical University, to further validate the drug's safety and efficacy [1] - The data obtained from this trial will provide critical support for the drug's final market application [1]